<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01873625</url>
  </required_header>
  <id_info>
    <org_study_id>Royan-RA-001</org_study_id>
    <nct_id>NCT01873625</nct_id>
  </id_info>
  <brief_title>Transplantation of Bone Marrow Derived Mesenchymal Stem Cells in Affected Knee Osteoarthritis by Rheumatoid Arthritis</brief_title>
  <official_title>Resurfacing Articular Cartilage With Mesenchymal Stem Cells Transplantation in Patients With Knee Joint Osteoarthritis Affected by Rheumatoid Arthritis: Randomized Triple Blind Clinical Trial Phase II/III (ACRCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royan Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Osteoarthritis of the knee is one of the most common causes of disability among elderly.
      Arthritis rheumatoid is an autoimmune disease which causes multi articular arthritis, such as
      knee osteoarthritis. As the disease progresses the cartilage become frustrated, surrounding
      bone react to become thicker and inflammation occurs in subchondral bone seen in T2-weighted
      MRI as increase in signal density. Patients are treated initially by pain management. In
      patients who don't response to first line treatment invasive treatment like total knee
      replacement is done. The investigators designed this clinical study with the aim of
      evaluating therapeutic effects of intra-articular injection of bone marrow mesenchymal stem
      cells (BM-MSCs) in 60 patients with knee osteoarthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study all eligible patients were randomly allocated into two study groups by a
      permuted block randomization method: group A (control group) received only routine medical
      therapies and placebo injected into there knees.. Group B received mesenchymal stem cells in
      addition of routine medical therapy.

      Patients were categorized according to the following stimulation protocols:

      To assess the outcomes, after mesenchymal stem cells transplantation at months 1,3,6 and 12
      we will examine the patients by: WOMAC questioners, DAS28 scoring , radiographies assessments
      and biochemical analysis with laboratory tests.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pain</measure>
    <time_frame>1month</time_frame>
    <description>Evaluation the pain reduction after mesenchymal stem cell transplantation that measured by VAS scaling.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>physical activity</measure>
    <time_frame>1month</time_frame>
    <description>evaluation the improvement of physical activity after mesenchymal stem cell transplantation that measured by WOMAC scoring.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>walking distance</measure>
    <time_frame>1month</time_frame>
    <description>Evaluation the walking distance after mesenchymal transplantation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Imaging</measure>
    <time_frame>6months</time_frame>
    <description>Evaluation the resurfacing of articular cartilage after mesenchymal transplantation by MRI and radio logic assessment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal salin injection in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mesencymal stem cell</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mesenchymal stem cell transplantation in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mesenchymal cell transplantation</intervention_name>
    <description>Mesenchymal stem cell transplantation in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.</description>
    <arm_group_label>mesencymal stem cell</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 to 65 years

          2. Body mass index (BMI) â‰¤30 kg/m2

          3. The presence of osteoarthritis based on MRI and American Rheumatism Association
             criteria since 6 months before invitation

        Exclusion Criteria:

        1. Response to routine treatment at last one year.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamid Gourabi, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Head of Royan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nasser Aghdami, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Head of regenerative medicine department, head of Royan cell therapy center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohsen Emadedin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Royan Institute,Department of regenerative medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Farhad gharibdoost, MD</last_name>
    <role>Study Director</role>
    <affiliation>President of rheumatologic association center of Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Soraya Shadmanfar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royan Institute, Department of regenerative medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royan Institute</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://RoyanInstitute.org</url>
  </link>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2013</study_first_submitted>
  <study_first_submitted_qc>June 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2013</study_first_posted>
  <last_update_submitted>June 7, 2013</last_update_submitted>
  <last_update_submitted_qc>June 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mesenchymal stem cells</keyword>
  <keyword>osteoarthritis</keyword>
  <keyword>arthritis rheumatoid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

